News | News By Subject | News by Disease News By Date | Search News

Muscular Dystrophy News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
PTC Therapeutics (PTCT) Buys Marathon Pharma's Controversial $89,000-Per-Year DMD Drug for $190 Million     3/16/2017
Catabasis (CATB) Plunges on DMD Drug Trial Failure     2/1/2017
JPM17: Sarepta (SRPT)'s New Numbers Impress Investors, Stock Gained $300 Million Overnight     1/11/2017
Humana (HUM) to Cover Sarepta (SRPT)'s Controversial DMD Drug But There's a Catch     10/27/2016
Sarepta (SRPT) Gets No Love From the FDA's New Drugs Director     10/21/2016
PTC Therapeutics (PTCT) Tanks After the FDA Denies DMD Drug Translarna Again     10/17/2016
Watch Out, Ionis Pharma (IONS): Could This Little Biotech’s Experimental SMA Treatment Be a Threat?     10/17/2016
Sarepta (SRPT) Goes for a New DMD Combo With New $562 Million+ Deal With Summit Therapeutics     10/4/2016
Saga Continues for Sarepta (SRPT) as FDA Head Calls for Retraction of 'Misleading' 2013 Study     9/23/2016
Victory at Last! Sarepta (SRPT) Stock Doubles as the FDA Finally Approves DMD Drug     9/20/2016
Turn the Page: Sarepta (SRPT) Stock Pops on Rumors DMD Drug Naysayer Leaves the FDA     9/15/2016
Sarepta (SRPT)’s Duchene Muscular Dystrophy Drug: Evaluating the Placebo Effect     8/19/2016
Sarepta (SRPT) Stock Surges After Government Website Indicates Firm is Recruiting for Phase III Study     8/5/2016
FDA Hits DMD Drugmaker Santhera (SANN.SW) With Lengthy Delay     7/14/2016
This Year’s Top 10 Disappointing Clinical Trials—So Far!     7/6/2016

News from Around the Web
PTC Therapeutics (PTCT)'s New $35,000 Price Tag For MD Drug Draws Criticism And Doubt     5/9/2017
Can Sarepta (SRPT) Continue To Live Up To The DMD Hype?     5/8/2017
More Senators Demand Answers From Marathon Pharma's CEO And His Pricey DMD Drug     3/6/2017
PTC Therapeutics (PTCT) Wants a Slice of Sarepta (SRPT)'s DMD Pie, Says Rejected Drug May Help Some Patients     10/7/2016
After Sarepta (SRPT)'s Win, BioMarin (BMRN) Wants a Piece of the Action Too     9/23/2016
Approving A Muscular Dystrophy Drug Exposes A Civil War At The FDA     9/20/2016
Approving Sarepta (SRPT)'s DMD Drug Could Force FDA To Get Creative     5/26/2016
Robotic Arm For Duchenne Patients Developed, University of Twente Reveals     1/25/2016
"Ringo The Dog" Helps Find Potential New Therapy For Muscular Dystrophy     11/18/2015
Scientists Make Diseased Cells Synthesize Their Own Drug, The Scripps Research Institute Reveals     9/4/2014
Viagra And Cialis Could Help Treat Duchenne Muscular Dystrophy, Cedars--Sinai Heart Institute Study     5/8/2014
What The Delay Of A Promising Muscular Dystrophy Drug Means For Patients, Investors And All Of Biotech     11/13/2013
Double Gene Flaws Lead to Rare Muscular Dystrophy, University of Rochester and Fred Hutchinson Cancer Research Center Study     11/14/2012
New Muscular Dystrophy Treatment Offers Hope, North Shore-Long Island Jewish Research Institute Study     3/24/2011
Human Protein Improves Muscle Function of Muscular Dystrophy in Mice, Brown University Study     12/28/2010

Press Releases
Sarepta (SRPT) Announces Its Partner, Genethon, Published New Micro-Dystrophin Gene Therapy Data In Nature Communications     7/27/2017
Clinigen And Sarepta (SRPT) Launch A Managed Access Program To Treat Patients With Duchenne Muscular Dystrophy Amenable To Exon 51 Skipping     7/19/2017
Santhera (SANN.SW)'s Raxone Receives First Positive EAMS Scientific Opinion From UK's MHRA In Duchenne Muscular Dystrophy     6/22/2017
Santhera (SANN.SW)’s Raxone Receives First Positive EAMS Scientific Opinion From UK’s MHRA In Duchenne Muscular Dystrophy     6/22/2017
Sarepta (SRPT) And Genethon Announce A Gene Therapy Research Collaboration For The Treatment Of Duchenne Muscular Dystrophy     6/21/2017
Solid Biosciences Strengthens Leadership Team To Advance Programs For Duchenne Muscular Dystrophy     6/7/2017
CD Access To Provide Special Access Program For Duchenne Muscular Dystrophy Patients In Canada     6/1/2017
Summit Therapeutics Completes Enrollment Of Phaseout DMD, A Phase II Clinical Trial Of Ezutromid In Patients With DMD     5/15/2017
Biophytis: First Patient-In In The United States And Opening Of 2 Clinical Centers For The SARA-OBS Study On Sarcopenia     5/11/2017
GTx, Inc. (GTXI) Announces Results From Preclinical Studies Of Sarms In Duchenne Muscular Dystrophy Models Published In Human Molecular Genetics     5/3/2017
Catabasis (CATB) Announces Favorable Results For Functional Assessments In The Movedmd Trial For Edasalonexent In Duchenne Muscular Dystrophy At American Academy of Neurology 69th Annual Meeting     4/25/2017
aTyr Pharma Announces Promising Top-Line Results From Resolaris Phase Ib/II Clinical Trial in Patients With Early Onset Facioscapulohumeral Muscular Dystrophy     4/24/2017
aTyr Pharma Announces Promising Top-Line Results From Resolaris Phase Ib/II Clinical Trial In Patients With Early Onset Facioscapulohumeral Muscular Dystrophy     4/24/2017
Biogen (BIIB)’s SPINRAZA (Nusinersen) Receives Positive CHMP Opinion For The Treatment Of Spinal Muscular Atrophy     4/24/2017
aTyr Pharma Presents Analyses Of Resolaris Phase Ib/II Trial In Patients With Limb Girdle Muscular Dystrophy 2B And Facioscapulohumeral Muscular Dystrophy At American Academy of Neurology 69th Annual Meeting     4/24/2017